Last reviewed · How we verify

rBet v1-FV

Allergopharma GmbH & Co. KG · Phase 2 active Biologic

rBet v1-FV is a Biologic drug developed by Allergopharma GmbH & Co. KG. It is currently in Phase 2 development. Also known as: Specific Immunotherapy, Spicific Immunotherapy.

At a glance

Generic namerBet v1-FV
Also known asSpecific Immunotherapy, Spicific Immunotherapy
SponsorAllergopharma GmbH & Co. KG
ModalityBiologic
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about rBet v1-FV

What is rBet v1-FV?

rBet v1-FV is a Biologic drug developed by Allergopharma GmbH & Co. KG.

Who makes rBet v1-FV?

rBet v1-FV is developed by Allergopharma GmbH & Co. KG (see full Allergopharma GmbH & Co. KG pipeline at /company/allergopharma-gmbh-co-kg).

Is rBet v1-FV also known as anything else?

rBet v1-FV is also known as Specific Immunotherapy, Spicific Immunotherapy.

What development phase is rBet v1-FV in?

rBet v1-FV is in Phase 2.

Related